RxDoctor Payments Data

Yira van der Linde, MD

Psychiatry · Pensacola, FLNPI 1770578585

Payments from drug & device makers

$725in general payments, 2019–2025

Across 46 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$259
  • Otsuka America Pharmaceutical, Inc.$158
  • Shire North American Group Inc$65
  • Takeda Pharmaceuticals U.S.A., Inc.$56
  • Ironshore Pharmaceuticals Inc.$52
  • Sunovion Pharmaceuticals Inc.$40
  • plus $97 from 5 others

What the payments were for

  • Food & beverage$69896%
  • Education$274%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$725 in reported general payments places this provider in the 55th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$58,445
Medicare patients
109
Services billed
523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine37$524,143
VraylarCariprazine Hcl25$35,033
Lurasidone Hcl72$9,970
VyvanseLisdexamfetamine Dimesylate16$6,115
Bupropion XlBupropion Hcl85$4,329
Lisdexamfetamine Dimesylate19$3,657
Trazodone Hcl104$3,075
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine45$3,072
Escitalopram Oxalate135$2,257
Vilazodone Hcl28$2,036
Buspirone Hcl64$1,475
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine36$1,182
Duloxetine Hcl62$1,028
Venlafaxine Hcl ErVenlafaxine Hcl46$1,027
Lamotrigine75$910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$259$35,03325 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$56$6,11516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →